 SAN DIEGO and TOKYO, May 19, 2021 PRNewswire -- MEI Pharma, Inc. NASDAQ: MEIP, a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. Kyowa Kirin, TSE: 4151, a global specialty pharmaceutical company that utilizes the latest biotechnology to discover and deliver novel medicines, today announced new data for zandelisib, an investigational phosphatidylinositol 3-kinase delta PI3Kδ inhibitor in clinical development for the treatment of B-cell malignancies. 